Home > Oncology > ASCO GI 2023 > ASCO GI 2023 Highlights Podcast

ASCO GI 2023 Highlights Podcast

Presented by
Robert van den Heuvel, Medicom
ASCO GI 2023

In this episode (12.08 minutes), Medicom’s correspondent covers 6 presentations from the ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2023), held in San Francisco (CA, US) from 19-21 January, 2023.
The topics discussed are:

  1. New standard-of-care for colorectal cancer
    The phase 3 SUNLIGHT trial demonstrated that bevacizumab plus trifluridine/tipiracil significantly improved overall survival and progression-free survival compared with trifluridine/tipiracil as a single agent in patients with refractory metastatic colorectal cancer.
  2. Zolbetuximab plus mFOLFOX6 scores in gastric cancer
    Zolbetuximab added to mFOLFOX6 improved the progression-free survival and overall survival of patients with claudin-18.2-positive HER2−negative, locally advanced, unresectable or metastatic, gastric or gastroesophageal junction adenocarcinoma, primary results of the SPOTLIGHT study revealed.
  3. New first-line option for metastatic pancreatic duct cancer
    The phase 3 NAPOLI-3 trial showed that liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) outperformed nab-paclitaxel plus gemcitabine in patients with untreated metastatic pancreatic ductal adenocarcinoma.
  4. Radiotherapy relieves hepatic pain in HCC and liver metastasis
    Single fraction radiation therapy added to best supportive care outperformed best supportive care only in reducing hepatic pain in patients with either end-stage hepatocellular carcinoma or liver metastasis. A trend was reported towards improved survival for patients receiving RT.
  5. Novel treatment option for advanced gastric cancer
    Regorafenib outperformed placebo in terms of overall survival in patients with refractory advanced gastric or oesophago-gastric junction cancer in the phase 3 INTEGRATE IIa trial, providing a new treatment option for this patient population.
  6. Excellent outcomes of LATG/LAPG in gastric cancer
    Patients with stage 1 gastric cancer displayed excellent long-term survival outcomes after laparoscopy-assisted total or proximal gastrectomy. According to the authors, the JCOG1401 study showed that laparoscopy-assisted total or proximal gastrectomy can result in comparable results as open procedures.

Enjoy listening!

Copyright ©2023 Medicom Medical Publishers

Posted on